Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI

PurposePlatinum-based chemotherapy remains the classic treatment option for patients with advanced non-small-cell lung cancer (NSCLC) who progress while receiving treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). In this study, we analyzed real-world outcomes of...

Full description

Bibliographic Details
Main Authors: Haiyi Deng, Xinqing Lin, Xiaohong Xie, Yilin Yang, Liqiang Wang, Jianhui Wu, Ming Liu, Zhanhong Xie, Yinyin Qin, Chengzhi Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
epidermal growth factor receptor gene (EGFR)
immune checkpoint inhibitor
immunotherapy
non-small-cell lung cancer
single-agent chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.700023/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.700023/full

Similar Items